Crizotinib is an oral small-molecule tyrosine kinase inhibitor that targets the ALK, MET, and ROS1 tyrosine kinases and is well known to induce clinically significant responses in NSCLC [22–24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.